Rozanolixizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Rozanolixizumab
Accession Number
DB14919
Description

Rozanolixizumab is under investigation in clinical trial NCT03861481 (A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy).

Type
Biotech
Groups
Investigational
Synonyms
Not Available

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Rozanolixizumab.
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Rozanolixizumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Rozanolixizumab.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Rozanolixizumab.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Rozanolixizumab.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Rozanolixizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rozanolixizumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Rozanolixizumab.
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Rozanolixizumab.
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Rozanolixizumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
P7186074QC
CAS number
1584645-37-3

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Enrolling by InvitationTreatmentMyasthenia Gravis1
3RecruitingTreatmentMyasthenia Gravis1
3RecruitingTreatmentPrimary Immune Thrombocytopenia2
2CompletedTreatmentMyasthenia Gravis1
2Enrolling by InvitationTreatmentChronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)1
2RecruitingTreatmentChronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)1
1CompletedBasic ScienceHealthy-volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 08:35 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates